Terms: = Ovarian cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
21 results:
1. Immunoglobulins and serum proteins impair anti-tumor NK cell effector functions in malignant ascites.
Hrvat A; Benders S; Kimmig R; Brandau S; Mallmann-Gottschalk N
Front Immunol; 2024; 15():1360615. PubMed ID: 38646521
[TBL] [Abstract] [Full Text] [Related]
2. Genome-wide DNA copy number profiling and bioinformatics analysis of ovarian cancer reveals key genes and pathways associated with distinct invasive/migratory capabilities.
Liu G; Ruan G; Huang M; Chen L; Sun P
Aging (Albany NY); 2020 Jan; 12(1):178-192. PubMed ID: 31895688
[TBL] [Abstract] [Full Text] [Related]
3. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by egfr/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract] [Full Text] [Related]
4. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
[TBL] [Abstract] [Full Text] [Related]
5. Cytoplasmic YAP expression is associated with prolonged survival in patients with lung adenocarcinomas and epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Sun PL; Kim JE; Yoo SB; Kim H; Jin Y; Jheon S; Kim K; Lee CT; Chung JH
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S610-8. PubMed ID: 24770679
[TBL] [Abstract] [Full Text] [Related]
6. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
[TBL] [Abstract] [Full Text] [Related]
7. Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.
Gottschalk N; Lang S; Kimmig R; Singh M; Brandau S
BMC Cancer; 2012 Oct; 12():451. PubMed ID: 23036052
[TBL] [Abstract] [Full Text] [Related]
8. Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.
Trinh XB; Tjalma WA; Dirix LY; Vermeulen PB; Peeters DJ; Bachvarov D; Plante M; Berns EM; Helleman J; Van Laere SJ; van Dam PA
PLoS One; 2011; 6(7):e22469. PubMed ID: 21799864
[TBL] [Abstract] [Full Text] [Related]
9. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling.
Davidson B; Espina V; Steinberg SM; Flørenes VA; Liotta LA; Kristensen GB; Tropé CG; Berner A; Kohn EC
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):791-9. PubMed ID: 16467090
[TBL] [Abstract] [Full Text] [Related]
10. clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer.
Tanaka Y; Miyamoto S; Suzuki SO; Oki E; Yagi H; Sonoda K; Yamazaki A; Mizushima H; Maehara Y; Mekada E; Nakano H
Clin Cancer Res; 2005 Jul; 11(13):4783-92. PubMed ID: 16000575
[TBL] [Abstract] [Full Text] [Related]
11. Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma.
Raspollini MR; Castiglione F; Garbini F; Villanucci A; Amunni G; Baroni G; Boddi V; Taddei GL
Int J Surg Pathol; 2005 Apr; 13(2):135-42. PubMed ID: 15864375
[TBL] [Abstract] [Full Text] [Related]
12. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (egfr), and Her-2/neu expression in ovarian cancer.
Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
[TBL] [Abstract] [Full Text] [Related]
13. Absence of evidence for HER2 amplification in nasopharyngeal carcinoma.
Yan J; Fang Y; Huang BJ; Liang QW; Wu QL; Zeng YX
Cancer Genet Cytogenet; 2002 Jan; 132(2):116-9. PubMed ID: 11850071
[TBL] [Abstract] [Full Text] [Related]
14. Detection of c-erbb-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer.
Seki A; Yoshinouchi M; Seki N; Kodama J; Miyagi Y; Kudo T
Int J Oncol; 2000 Jul; 17(1):103-6. PubMed ID: 10853025
[TBL] [Abstract] [Full Text] [Related]
15. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure.
Goff BA; Ries JA; Els LP; Coltrera MD; Gown AM
Gynecol Oncol; 1998 Sep; 70(3):378-85. PubMed ID: 9790791
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic significance of p105 (c-erbb-2 HER2/neu) serum levels in patients with ovarian cancer.
Meden H; Marx D; Schauer A; Wuttke W; Kuhn W
Anticancer Res; 1997; 17(1B):757-60. PubMed ID: 9066616
[TBL] [Abstract] [Full Text] [Related]
17. nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters.
Scambia G; Ferrandina G; Marone M; Benedetti Panici P; Giannitelli C; Piantelli M; Leone A; Mancuso S
J Clin Oncol; 1996 Feb; 14(2):334-42. PubMed ID: 8636741
[TBL] [Abstract] [Full Text] [Related]
18. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.
Scambia G; Benedetti-Panici P; Ferrandina G; Distefano M; Salerno G; Romanini ME; Fagotti A; Mancuso S
Br J Cancer; 1995 Aug; 72(2):361-6. PubMed ID: 7640219
[TBL] [Abstract] [Full Text] [Related]
19. Concurrent abnormal expression of erbb-2, myc and ras genes is associated with poor outcome of ovarian cancer patients.
Katsaros D; Theillet C; Zola P; Louason G; Sanfilippo B; Isaia E; Arisio R; Giardina G; Sismondi P
Anticancer Res; 1995; 15(4):1501-10. PubMed ID: 7654038
[TBL] [Abstract] [Full Text] [Related]
20. c-erbb-2 and p53 expression in fallopian tube carcinoma.
Lacy MQ; Hartmann LC; Keeney GL; Cha SC; Wieand HS; Podratz KC; Roche PC
Cancer; 1995 Jun; 75(12):2891-6. PubMed ID: 7773939
[TBL] [Abstract] [Full Text] [Related]
[Next]
